Biofrontera Sets 2026 Guidance and Highlights Growing U.S. Earn-Out Income

The latest announcement is out from Biofrontera ( (DE:B8FK) ).

Biofrontera AG has issued financial guidance for 2026, forecasting sales revenue of EUR 14 million to EUR 16 million from its ongoing operations, compared with adjusted sales of EUR 19 million and unadjusted EUR 13 million expected for 2025. The company also anticipates an earn-out from Biofrontera Inc. of EUR 3.5 million to EUR 4.5 million in 2026 based on U.S. Ameluz sales, up from EUR 1.8 million in 2025, underscoring the continuing financial relevance of the divested U.S. business.

Management expects adjusted EBITDA of EUR 3.5 million to EUR 5.1 million in 2026, broadly in line with the 2025 adjusted range of EUR 4 million to EUR 5 million, while unadjusted EBITDA is guided between EUR -0.5 million and EUR +0.5 million. Due to IFRS rules after the sale of its U.S. operations, Biofrontera is providing both adjusted and unadjusted figures, as revenues and earnings from the discontinued U.S. business, including earn-outs, will be reported separately as a net result from discontinued operations, affecting comparability and transparency for investors.

More about Biofrontera

Biofrontera AG is a German biopharmaceutical company based in Leverkusen, focused on dermatological therapies. The company’s portfolio includes the prescription drug Ameluz for the treatment of skin diseases, with a strong commercial emphasis on U.S. market sales through its former U.S. business unit, now reflected via earn-out payments from Biofrontera Inc.

Average Trading Volume: 1,820

Technical Sentiment Signal: Sell

Current Market Cap: €15.86M

Find detailed analytics on B8FK stock on TipRanks’ Stock Analysis page.